Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?

Neuro-Oncology

Volumn 17, Issue 7, 2015, Pages 1022-1028

  Wang, Tony J C ^a   Saad, Shumaila ^a   Qureshi, Yasir H ^a   Jani, Ashish ^a   Nanda, Tavish ^a   Yaeh, Andrew M ^a   Rozenblat, Tzlil ^a   Sisti, Michael B ^a,b   Bruce, Jeffrey N ^a,b   McKhann, Guy M ^a,b   Lesser, Jeraldine ^a   Halmos, Balazs ^a   Stoopler, Mark B ^a   Lassman, Andrew B ^a,b   Cheng, Simon K ^a   Isaacson, Steven R ^a  

^a Department of Medicine   (United States)

^b Herbert Irving Comprehensive Cancer Center ^*  (United States)

Author keywords

brain metastases; mutations; non small cell lung cancer; stereotactic radiosurgery; targeted therapy

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; K RAS PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; EML4 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; KRAS PROTEIN, HUMAN; PROTEIN P21; PROTEIN TYROSINE KINASE; SERINE PROTEINASE;

ADULT; AGED; ALK GENE; ARTICLE; BRAIN METASTASIS; CANCER CONTROL; CANCER RADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; EGFR GENE; ELM4 GENE; EXON; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSTIC ASSESSMENT; VERY ELDERLY; WILD TYPE; BRAIN NEOPLASMS; GENETICS; LUNG TUMOR; MORTALITY; MUTATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIOSURGERY; SECONDARY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS P21(RAS); RADIOSURGERY; RECEPTOR PROTEIN-TYROSINE KINASES; SERINE ENDOPEPTIDASES;

EID: 84936760824     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov043     Document Type: Article

References (28)

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367-1380.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-1500.
3. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990;323(9):561-565.
4. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561-566.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-2139.
6. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis. J Natl Cancer Inst. 2013;105(9): 595-605.
7. Antoniu SA. Crizotinib for EML4-ALK positive lung adenocarcinoma: A hope for the advanced disease? Evaluation of Kwak.
8. Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703.
9. Expert Opin Ther Targets. 2011;15(3):351-353.
10. Sorensen JB, Hansen HH, Hansen M, et al. Brain metastases in adenocarcinoma of the lung: Frequency, risk groups, and prognosis. J Clin Oncol. 1988;6(9):1474-1480.
11. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865-2872.
12. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745-751.
13. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21(13):2529-2536.
14. Bhangoo SS, Linskey ME, Kalkanis SN. Evidence-based guidelines for the management of brain metastases. Neurosurg Clin N Am. 2011;22(1):97-104, viii.
15. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multiinstitutional analysis of 4, 259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655-661.
16. Hsiao SH, Lin HC, Chou YT, et al. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients. Lung Cancer. 2013;81(3):455-461.
17. Johung KL, Yao X, Li F, et al. A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer. Clin Cancer Res. 2013;19(19):5523-5532
18. Grommes C, Oxnard GR, Kris MG, et al. Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011;13(12): 1364-1369.
19. Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res. 2012;18(4):938-944.
20. Getman V, Devyatko E, Dunkler D, et al. Prognosis of patients with non-small cell lung cancer with isolated brain metastases undergoing combined surgical treatment. Eur J Cardiothorac Surg. 2004;25(6):1107-1113.
21. Arrieta O, Villarreal-Garza C, Zamora J, et al. Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation. Radiat Oncol. 2011;6:166.
22. Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1, 960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70(2): 510-514.
23. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-957.
24. Eichler AF, Kahle KT, Wang DL, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010;12(11):1193-1199.
25. Cai L, Zhu JF, Zhang XW, et al. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer. J Neurooncol. 2014; 120:423-430.
26. Mak KS, Gainor JF, Niemierko A, et al. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brainmetastases. Neuro Oncol. 2014;16:296-302.
27. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: A prospective trial. Ann Oncol. 2004;15(7):1042-1047.
28. Cappuzzo F, Calandri C, Bartolini S, et al. ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): Report of four cases. Br J Cancer. 2003;89(2):246-247.